Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
ZacksLyra Therapeutics (LYRA) delivered earnings and revenue surprises of -34.62% and 33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?